David M. Reese's Insider Trades & SAST Disclosures
David M. Reese's most recent trade in AMGEN Inc. was a trade of 22,944 Nqso (Right to Buy) done . Disclosure was reported to the exchange on May 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David M. Reese.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 22,944 | 22,944 | - | - | Nqso (Right to Buy) | |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 3,549 | 42,116 (0%) | 0% | 0 | Common Stock | |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 283.78 per share. | 02 May 2025 | 702 | 39,232 (0%) | 0% | 283.8 | 199,214 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 283.78 per share. | 02 May 2025 | 665 | 38,567 (0%) | 0% | 283.8 | 188,714 | Common Stock |
| AMGEN Inc. | Reese David M. | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 288.56 per share. | 30 Apr 2025 | 768 | 39,934 (0%) | 0% | 288.6 | 221,614 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 313.71 per share. | 17 Mar 2025 | 3,635 | 40,702 (0%) | 0% | 313.7 | 1,140,336 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 7,277 | 44,199 (0%) | 0% | 0 | Common Stock | |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 304.44 per share. | 19 Feb 2025 | 25,225 | 36,922 (0%) | 0% | 304.4 | 7,679,524 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 8,711 | 0 | - | - | Nqso (Right to Buy) | |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 156.35 per share. | 19 Feb 2025 | 8,711 | 70,858 (0%) | 0% | 156.4 | 1,361,965 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 293.22 per share. | 19 Feb 2025 | 8,711 | 62,147 (0%) | 0% | 293.2 | 2,554,224 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 20,767 | 20,767 | - | - | Nqso (Right to Buy) | |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 3,196 | 61,889 (0%) | 0% | 0 | Common Stock | |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 311.29 per share. | 05 May 2024 | 633 | 58,693 (0%) | 0% | 311.3 | 197,047 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 277.37 per share. | 02 May 2024 | 650 | 59,326 (0%) | 0% | 277.4 | 180,291 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 276.38 per share. | 30 Apr 2024 | 690 | 59,976 (0%) | 0% | 276.4 | 190,702 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 268.87 per share. | 18 Mar 2024 | 6,202 | 60,666 (0%) | 0% | 268.9 | 1,667,532 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 12,407 | 66,653 (0%) | 0% | 0 | Common Stock | |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 231.89 per share. | 05 May 2023 | 594 | 54,114 (0%) | 0% | 231.9 | 137,743 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 32,250 | 32,250 | - | - | Nqso (Right to Buy) | |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 3,814 | 55,527 (0%) | 0% | 0 | Common Stock | |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 235.97 per share. | 02 May 2023 | 819 | 54,708 (0%) | 0% | 236.0 | 193,259 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.74 per share. | 30 Apr 2023 | 666 | 51,713 (0%) | 0% | 239.7 | 159,667 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 234.57 per share. | 17 Mar 2023 | 3,978 | 52,379 (0%) | 0% | 234.6 | 933,119 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 7,947 | 56,167 (0%) | 0% | 0 | Common Stock | |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 272.06 per share. | 02 Nov 2022 | 2,440 | 48,136 (0%) | 0% | 272.1 | 663,826 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 236.10 per share. | 05 May 2022 | 575 | 50,307 (0%) | 0% | 236.1 | 135,758 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 31,817 | 31,817 | - | - | Nqso (Right to Buy) | |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 3,897 | 51,652 (0%) | 0% | 0 | Common Stock | |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 230.92 per share. | 02 May 2022 | 770 | 50,882 (0%) | 0% | 230.9 | 177,808 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 249.87 per share. | 27 Apr 2022 | 184 | 47,755 (0%) | 0% | 249.9 | 45,976 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 235.86 per share. | 18 Mar 2022 | 4,995 | 47,939 (0%) | 0% | 235.9 | 1,178,121 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 9,989 | 52,714 (0%) | 0% | 0 | Common Stock | |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 34,782 | 34,782 | - | - | Nqso (Right to Buy) | |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 4,006 | 46,326 (0%) | 0% | 0 | Common Stock | |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.64 per share. | 30 Apr 2021 | 1,109 | 45,217 (0%) | 0% | 239.6 | 265,761 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.64 per share. | 30 Apr 2021 | 745 | 44,472 (0%) | 0% | 239.6 | 178,532 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 255.52 per share. | 27 Apr 2021 | 174 | 42,320 (0%) | 0% | 255.5 | 44,460 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.42 per share. | 19 Mar 2021 | 1,401 | 42,494 (0%) | 0% | 244.4 | 342,432 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 2,803 | 43,715 (0%) | 0% | 0 | Common Stock | |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 2,300 | 0 | - | - | Nqso (Right to Buy) | |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.69 per share. | 16 Feb 2021 | 2,300 | 42,059 (0%) | 0% | 54.7 | 125,787 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 237.21 per share. | 16 Feb 2021 | 1,147 | 40,912 (0%) | 0% | 237.2 | 272,080 | Common Stock |
| AMGEN Inc. | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 216.94 per share. | 02 Nov 2020 | 2,125 | 39,619 (0%) | 0% | 216.9 | 460,998 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges